Professor Kausik Ray is a professor of Public Health in the Department of Primary Care and Public Health in the School of Public Health at Imperial College London, UK and an honorary consultant at the St George’s University Hospitals NHS Foundation Trust, London, UK. Professor Ray received his medical education (MB ChB) at the University of Birmingham Medical School, UK in 1991 and his MD at the University of Sheffield, UK in 2004. He also received a postdoctoral fellowship from Harvard Medical School, Boston, MA, USA and an MPhil in epidemiology from the University of Cambridge, UK in 2007.
Professor Ray is a fellow of the American College of Cardiology (ACC), the European Society of Cardiology (ESC), the American Heart Association (AHA) and the Royal College of Physicians (RCP), as well as a member of the British Cardiovascular Society (BCS) and the European Atherosclerosis Society (EAS). He has been the national lead investigator, served on the committees or been principal investigator for several major medical trials including T-EMERGE 8, SOLID-TIMI 52, SAVOR-TIMI 53, DAL-Outcomes II, Dal-ACUTE, ODYSSEY OUTCOMES, DECLARE-TIMI 58, CAMELLIA TIMI 61 and THEMIS, and is currently involved in eight ongoing trials.
Professor Ray is a section editor for Heart, an international editorial board member for the European Heart Journal, an editorial board member for Archives of Medical Science and a reviewer for Proceedings of the National Academy of Sciences. He is also part of the EAS consensus panel.
Professor Ray’s research interests have focused on the prevention and reduction of coronary events, preventive cardiology and diabetes. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control and the risks/benefits of aspirin therapy – these studies have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMA. He continues to investigate the role of lipids, lipoproteins in diabetes, inflammation, thrombosis and coronary events and has received numerous research grants, from bodies including the British Heart Foundation and the Wellcome Trust Project.
Currently, Professor Ray leads the European Atherosclerosis Society-Familial Hypercholesterolaemia (EAS-FH) Studies Collaboration and is the senior principal investigator for the TOGETHER study, looking at cardiometabolic risk in vascular health checks for 250,000 people in London. During his time as professor of cardiovascular disease prevention at St George’s University, he developed and led the integrated care pathway for patients with acute coronary syndrome – the first electronic pathway in the world for such patients.